ATE404218T1 - Rekombinante bcg-impfstoffe gegen intrazelluläre pathogene und anwendungsverfahren - Google Patents

Rekombinante bcg-impfstoffe gegen intrazelluläre pathogene und anwendungsverfahren

Info

Publication number
ATE404218T1
ATE404218T1 AT01927074T AT01927074T ATE404218T1 AT E404218 T1 ATE404218 T1 AT E404218T1 AT 01927074 T AT01927074 T AT 01927074T AT 01927074 T AT01927074 T AT 01927074T AT E404218 T1 ATE404218 T1 AT E404218T1
Authority
AT
Austria
Prior art keywords
intracellular pathogens
methods
recombinant
vaccines
immunotherapeutics
Prior art date
Application number
AT01927074T
Other languages
English (en)
Inventor
Marcus Horwitz
Gunter Harth
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE404218T1 publication Critical patent/ATE404218T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT01927074T 2000-04-17 2001-04-16 Rekombinante bcg-impfstoffe gegen intrazelluläre pathogene und anwendungsverfahren ATE404218T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/550,468 US6471967B1 (en) 2000-04-17 2000-04-17 Recombinant intracellular pathogen vaccines and methods for use

Publications (1)

Publication Number Publication Date
ATE404218T1 true ATE404218T1 (de) 2008-08-15

Family

ID=24197308

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01927074T ATE404218T1 (de) 2000-04-17 2001-04-16 Rekombinante bcg-impfstoffe gegen intrazelluläre pathogene und anwendungsverfahren

Country Status (12)

Country Link
US (1) US6471967B1 (de)
EP (1) EP1274453B1 (de)
JP (1) JP4868682B2 (de)
CN (1) CN1437479B (de)
AT (1) ATE404218T1 (de)
AU (1) AU5355801A (de)
CA (1) CA2406225C (de)
DE (1) DE60135318D1 (de)
ES (1) ES2315281T3 (de)
RU (1) RU2266132C2 (de)
WO (1) WO2001078774A2 (de)
ZA (1) ZA200209304B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7300660B2 (en) * 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US6924118B2 (en) * 2000-04-17 2005-08-02 The Regents Of The University Of California Recombinant intracellular pathogen immunogenic compositions and methods for use
WO2003089462A2 (en) * 2002-04-16 2003-10-30 Jun Liu Tuberculosis vaccines including recombinant bcg strains expressing alanine dehydrogenase, serine dehydratase and/or glutamine synthetase
DK2206514T3 (da) 2003-10-16 2014-04-22 Univ California Rekombinante intracellulære patogene immunogene sammensætninger og metoder til anvendelse
US8383132B2 (en) * 2003-10-16 2013-02-26 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US8287879B2 (en) 2003-10-16 2012-10-16 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US20100047286A1 (en) * 2004-12-01 2010-02-25 Aeras Global Tb Vaccine Foundation Recombinant BCG strains with enhanced ability to escape the endosome
GB0709373D0 (en) * 2007-05-16 2007-06-27 Thrombosis Res Inst BCG-based anti-atheroma vaccine
CN102186500A (zh) * 2008-10-20 2011-09-14 苏黎世大学 结核分枝杆菌疫苗
WO2011159814A2 (en) * 2010-06-15 2011-12-22 The Regents Of The University Of California Novel live recombinant booster vaccine against tuberculosis
EP2654783B1 (de) * 2010-12-21 2016-10-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Rekombinante mycobacterium als impfstoff

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807723A (en) 1987-03-02 1998-09-15 Whitehead Institute For Biomedical Research Homologously recombinant slow growing mycobacteria and uses therefor
WO1988006626A1 (en) 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine
US5591632A (en) 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
JP2903414B2 (ja) 1989-05-31 1999-06-07 味の素株式会社 抗酸菌分泌発現ベクター及び抗酸菌
JPH07502646A (ja) 1991-10-21 1995-03-23 メディミューン，インコーポレーテッド リポタンパク質の分泌シグナルをコード化するｄｎａを含む細菌発現ベクター
US5736367A (en) 1992-03-31 1998-04-07 Medimmune, Inc. Vectors and prokaryotes which autocatalytically delete antibiotic resistance
US5679515A (en) 1994-10-03 1997-10-21 Pathogenesis Corporation Mycobacterial reporter strains and uses thereof
US5700683A (en) 1995-02-17 1997-12-23 Pathogenesis Corporation Virulence-attenuating genetic deletions deleted from mycobacterium BCG
US5869057A (en) 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance
RU2112543C1 (ru) * 1996-09-26 1998-06-10 Александр Григорьевич Хоменко Иммуномодулирующее лекарственное средство

Also Published As

Publication number Publication date
EP1274453A2 (de) 2003-01-15
JP4868682B2 (ja) 2012-02-01
CA2406225C (en) 2012-06-26
WO2001078774A3 (en) 2002-03-28
CN1437479A (zh) 2003-08-20
CN1437479B (zh) 2012-12-05
ZA200209304B (en) 2004-08-13
ES2315281T3 (es) 2009-04-01
AU5355801A (en) 2001-10-30
US6471967B1 (en) 2002-10-29
DE60135318D1 (de) 2008-09-25
CA2406225A1 (en) 2001-10-25
EP1274453B1 (de) 2008-08-13
JP2004507453A (ja) 2004-03-11
RU2266132C2 (ru) 2005-12-20
RU2002130716A (ru) 2004-03-27
WO2001078774A2 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
Andongma et al. In silico design of a promiscuous chimeric multi-epitope vaccine against Mycobacterium tuberculosis
DE60142772D1 (de) Membranvesikel (omv) impfstoff, der n. meningitidis serogruppe b membranproteine enthält
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
ATE404218T1 (de) Rekombinante bcg-impfstoffe gegen intrazelluläre pathogene und anwendungsverfahren
NO20071609L (no) Immunogen sammensetning for anvendelse ved vaksinering mot stafylokokker
ATE501726T1 (de) Zusammensetzung mit immunogenen mikroteilchen
CY1112589T1 (el) Ανοσογονος συνθεση που περιεχει ανοσοενισχυτικο
GB0123580D0 (en) Vaccine
ATE350057T1 (de) Impfstoffzusammesetzung
CY1114243T1 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
NO20111324A1 (no) Rekombinant MVA-virus
BR9910749A (pt) Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma
GB2255093A (en) Hiv-1 core protein fragments
WO2001039803A3 (en) Interleukin-1 muteins useful as vaccine adjuvants
MX2020008454A (es) Composicion inmunogenica que comprende antigenos estafilococicos.
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
WO2005037222A3 (en) Recombinant intracellular pathogen immunogenic compositions and methods for use
ATE487489T1 (de) Rekombinante intrazellulärepathogen-immunogene zusammensetzungen und anwendungsverfahren
Pirdel et al. Immune response to recombinant Leishmania infantum lipophosphoglycan 3 plus CpG oligodeoxynucleotides in BALB/c mice
GB0110851D0 (en) Vaccine
MX2022001937A (es) Composicion inmunogenica.
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
BRPI0416178A (pt) método de incorporação de antìgeno em vesìculas de membrana externa de bactérias neisseria e formulações de vacina resultantes
WO2005023295A3 (en) Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties